SLC5A2 and hydrops fetalis: Meta‐analysis of six randomized controlled trials, demonstrated that sodium‐glucose cotransporter‐2 (SGLT2) inhibitors substantially reduce MACE, particularly decreasing the risk of HF hospitalization and progression of kidney disease in type 2 diabetes patients.54